China At Forefront Of Next Generation Sequencing: BGI CEO
This article was originally published in PharmAsia News
Executive Summary
From screening for cancer to providing individualized treatment, from rare diseases to the first in vitro fertilized (IVF) baby with modified genes, China has much to offer in the heating global race for next generation gene sequencing. Big data and the internet of genomics are just some examples, says Wang Jun, CEO of BGI, the world’s largest genomics organization.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.